Products

EmpowerCTA+

EmpowerCTA+

Related Content

Bracco's Syringeless MR Injector Receives FDA Approval
News | FDA
Bracco's Syringeless MR Injector Receives FDA Approval

Nov. 25, 2025 —Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

Time November 26, 2025
arrow
Huntsman Cancer Institute Opens Specialized Angiography-CT Suite
News | Interventional Radiology
Huntsman Cancer Institute Opens Specialized Angiography-CT Suite

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
Sponsored Content | Videos | Radiology Business
VIDEO: Talking Trends with Bayer Radiology — Navigating Market Disruptions to Your CT Suite

Bayer Radiology’s Barbara Ruhland and Thom Kinst discuss how radiology departments can address the many different ...

Time October 09, 2025
arrow
Study: Contrast-Enhanced Ultrasound is Safe, Saves lives
News | Ultrasound Imaging
Study: Contrast-Enhanced Ultrasound is Safe, Saves lives

May 14, 2025 — A comprehensive new study based on nationwide claims data from more than 11 million patients shows that ...

Time May 14, 2025
arrow
Viz 3D CTA Delivers Enhanced Imaging, Accelerates Clinical Decision-Making
News | Cardiac Imaging
Viz 3D CTA Delivers Enhanced Imaging, Accelerates Clinical Decision-Making

April 30, 2025 – Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has launched Viz ...

Time May 02, 2025
arrow
Bracco and Blue Earth Diagnostics has announced the appointment of Marco Campione as new CEO, effective immediately. Campione succeeds David Gauden, D. Phil., who now assumes the role of CEO of Bracco subsidiary Blue Earth Therapeutics.
News | Radiology Business
Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
Swedish biotech company Ascelia Pharma has announced its liver imaging drug candidate, Orviglance, significantly improved visualization of focal liver lesions, having successfully met the primary endpoint in the pivotal Phase 3 study, SPARKLE. CEO Magnus Corftizen shown here, offered an update on the first-in-class contrast agent for use in liver MRI in patients with severely impaired kidney function which has been granted FDA Orphan Drug Designation.
News | Contrast Media
Ascelia Pharma Meets Primary Endpoint in Phase 3 Study of Orviglance Liver Imaging Contrast Agent Drug Candidate

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
LUMISIGHT and Lumicell Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from second surgeries
News | FDA
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
Collaboration includes robust education and training to support radiologists and imaging specialists
News | Mammography
Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
The latest MyBreastAI Suite supports clinicians in accelerating breast cancer detection, while the company’s Pristina Bright solution helps healthcare providers start a new contrast program
News | Mammography
GE HealthCare to feature Mobile Mammography Screening Truck along with Latest AI Platform as part of SBI2024 Breast Cancer Imaging Showcase

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now